<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03220126</url>
  </required_header>
  <id_info>
    <org_study_id>16861</org_study_id>
    <secondary_id>I9O-MC-AABA</secondary_id>
    <secondary_id>2017-001242-10</secondary_id>
    <nct_id>NCT03220126</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants</brief_title>
  <official_title>An Assessment of the Absolute and Relative Bioavailability of Subcutaneous Doses of LY3074828 When Coadministered With LY9999QS to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the amount of the study drug, LY3074828, that gets&#xD;
      into the blood stream and how long it takes the body to get rid of LY3074828 when given&#xD;
      together with LY9999QS compared to LY3074828 alone. The tolerability of the different&#xD;
      formulations will also be evaluated and information about any side effects experienced will&#xD;
      be collected.&#xD;
&#xD;
      Screening is required within 28 days prior to the start of the study. For each participant&#xD;
      the total duration of the clinical trial will be approximately 13 weeks, not including&#xD;
      screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Actual">February 23, 2018</completion_date>
  <primary_completion_date type="Actual">February 23, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Treatments 2 and 3 of LY900021 will be administered in parallel with LY3074828. Treatments 2, 3, and 4 of LY900021 will be administered sequentially pending a safety review after administration of Treatments 2 and 3.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY3074828</measure>
    <time_frame>Baseline through Day 85</time_frame>
    <description>PK: AUC of LY3074828</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3074828 - Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous (IV) dose of LY3074828</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900021 - Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900021 - Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY900021 - Treatment 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY3074828</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3074828 - Treatment 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY900021</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY900021 - Treatment 2</arm_group_label>
    <arm_group_label>LY900021 - Treatment 3</arm_group_label>
    <arm_group_label>LY900021 - Treatment 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have venous access sufficient to allow for blood sampling and administration of&#xD;
             investigational product&#xD;
&#xD;
          -  Have clinical laboratory test results within normal reference range for the&#xD;
             investigative site, or results with acceptable deviations that are judged to be not&#xD;
             clinically significant by the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Must not have an average weekly alcohol intake that exceeds 21 units/week (males) and&#xD;
             14 units/week (females)&#xD;
&#xD;
          -  Must not show evidence of active or latent tuberculosis (TB)&#xD;
&#xD;
          -  Must not have received live vaccine(s) (including attenuated live vaccines and those&#xD;
             administered intranasally) within 1 month of screening, or intend to during the study&#xD;
&#xD;
          -  Must not be immunocompromised&#xD;
&#xD;
          -  Must not have known hypersensitivity to hyaluronidases&#xD;
&#xD;
          -  Must not have received treatment with biologic agents (e.g. monoclonal antibodies,&#xD;
             including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior&#xD;
             to dosing&#xD;
&#xD;
          -  Must not have significant allergies to humanised monoclonal antibodies&#xD;
&#xD;
          -  Must not have clinically significant multiple or severe drug allergies, or intolerance&#xD;
             to topical corticosteroids, or sever post treatment hypersensitivity reactions&#xD;
&#xD;
          -  Must not have had lymphoma, leukemia, or any malignancy within the past 5 years except&#xD;
             for basal cell or squamous epithelial carcinomas of the skin that have been resected&#xD;
             with no evidence of metastatic disease for 3 years&#xD;
&#xD;
          -  Must not have had breast cancer within the past 10 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirikizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

